Boston Scientific Invests $1.5B for 34% Stake in MiRus

Deal Summary

Boston Scientific announced a $1.5 billion investment to acquire a 34% stake in MiRus LLC, a developer of a nickel‑free TAVR system. The deal gives Boston Scientific a foothold in the transcatheter aortic valve replacement market and includes an option to purchase the remaining shares for up to $3 billion in the future.